4 Result: DexCom
Momentum Builds: DexCom and Intel's Upbeat Results, Outlook
October 27th, 2023
DexCom, Inc. (Nasdaq: DXCM), a leading player in diabetes management technology, delivered an impressive performance in the third quarter of 2023, reporting adjusted earnings per share (EPS) of $0.50. This surpassed the consensus EPS estimate of $0.3. Read more
DexCom Gains Pre-Market Traction on Financial Figures, Bullish Views
July 28th, 2023
DexCom, Inc. (Nasdaq: DXCM) delivered strong results in the second quarter of 2023, with earnings per share (EPS) of $0.34 and revenues of $871.30 million, surpassing the consensus estimate of $0.23 EPS on revenue of $841.62 million. In response t. Read more
Health Canada OKs Dexcom G7; HC Wainwright Bullish on Ensysce, LifeMD, Genfit
July 04th, 2023
Dexcom, Inc. (Nasdaq: DXCM) received approval from Health Canada for the Dexcom G7 Continuous Glucose Monitoring System for all types of diabetes, ages two and older. This technology can help manage diabetes more effectively and has been shown to red. Read more
DexCom Boosts Outlook; Analysts Bullish on Chipotle, Clean Harbors, and Roivant
June 25th, 2023
DexCom, Inc. (Nasdaq: DXCM) is making significant strides in its financial performance, leading the company to update its year-end 2025 revenue targets. With strong performance in the first two years of the target period, DexCom now expects to achiev. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Wall Street Eyes Ciena, lululemon, and Broadcom Ahead of Earnings
December 07th, 2025Earnings Watch: What to Expect from Electrovaya, Nordson, and Synopsys
December 07th, 2025Earnings on Deck: AeroVironment, AutoZone, and Core & Main Set to Report
December 07th, 2025December 05th, 2025FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025
Member Login